Jump to content

Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate

Add links
From Wikipedia, the free encyclopedia
(Redirected from Estandron Prolongatum)
EB/EPP/TP/TPP/TiC
Combination of
Estradiol benzoateEstrogen
Estradiol phenylpropionateEstrogen
Testosterone propionateAndrogen; Anabolic steroid
Testosterone phenylpropionateAndrogen; Anabolic steroid
Testosterone isocaproateAndrogen; Anabolic steroid
Clinical data
Trade namesEstandron Prolongatum, Lynandron Prolongatum, Mixogen
Other namesEB/EPP/TP/TPP/TiC
Routes of
administration		Intramuscular injection
Identifiers
CAS Number
PubChem CID
ChemSpider

Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate (EB/EPP/TP/TPP/TiC), sold under the brand names Estandron Prolongatum, Lynandron Prolongatum, and Mixogen, was an injectable combination medication of the estrogens estradiol benzoate (EB) and estradiol phenylpropionate (EPP) and the androgens/anabolic steroids testosterone propionate (TP), testosterone phenylpropionate (TPP), and testosterone isocaproate (TiC) which was used in menopausal hormone therapy for women.[1][2] It was also used to suppress lactation in postpartum women.[3][4]

The medication was provided in the form of 1 mL ampoules and 2 mL vials containing 1 mg/mL EB, 4 mg/mL EPP, 20 mg/mL TP, 40 mg/mL TPP, and 40 mg/mL TiC in an oil solution and was administered by intramuscular injection.[1][5][6] EB/EPP/TP/TPP/TiC reportedly has a duration of about 14 days.[7]

Estandron Prolongatum, Lynandron Prolongatum, and Mixogen were all introduced for medical use by 1956.[8][9] Oral tablet products with the same brand names of Estandron, Lynandron, and Mixogen, containing ethinylestradiol and methyltestosterone, were marketed around the same time, and should not be confused with the injectable products.[8][1][10] Estandron Prolongatum, Lynandron Prolongatum, and Mixogen remained marketed as late as the 1980s.[6][4][11] EB/EPP/TP/TPP/TiC appears to no longer be marketed.[12][13][14]

Androgen replacement therapy formulations and dosages used in women
Route Medication Major brand names Form Dosage
Oral Testosterone undecanoate Andriol, Jatenzo Capsule 40–80 mg 1x/1–2 days
Methyltestosterone Metandren, Estratest Tablet 0.5–10 mg/day
Fluoxymesterone Halotestin Tablet 1–2.5 mg 1x/1–2 days
Normethandronea Ginecoside Tablet 5 mg/day
Tibolone Livial Tablet 1.25–2.5 mg/day
Prasterone (DHEA)b – Tablet 10–100 mg/day
Sublingual Methyltestosterone Metandren Tablet 0.25 mg/day
Transdermal Testosterone Intrinsa Patch 150–300 μg/day
AndroGel Gel, cream 1–10 mg/day
Vaginal Prasterone (DHEA) Intrarosa Insert 6.5 mg/day
Injection Testosterone propionatea Testoviron Oil solution 25 mg 1x/1–2 weeks
Testosterone enanthate Delatestryl, Primodian Depot Oil solution 25–100 mg 1x/4–6 weeks
Testosterone cypionate Depo-Testosterone, Depo-Testadiol Oil solution 25–100 mg 1x/4–6 weeks
Testosterone isobutyratea Femandren M, Folivirin Aqueous suspension 25–50 mg 1x/4–6 weeks
Mixed testosterone esters Climacterona Oil solution 150 mg 1x/4–8 weeks
Omnadren, Sustanon Oil solution 50–100 mg 1x/4–6 weeks
Nandrolone decanoate Deca-Durabolin Oil solution 25–50 mg 1x/6–12 weeks
Prasterone enanthatea Gynodian Depot Oil solution 200 mg 1x/4–6 weeks
Implant Testosterone Testopel Pellet 50–100 mg 1x/3–6 months
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.

See also

[edit]

References

[edit]
  1. ^ a b c Hager HH, Kern W, List PH, Roth HJ (29 July 2013). Hagers Handbuch der Pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Ärzte und Medizinalbeamte: Wirkstoffgruppen II Chemikalien und Drogen (A-AL). Springer-Verlag. pp. 141, 157, 185. ISBN 978-3-662-25655-8.
  2. ^ Schirren C (14 March 2013). "Die Sexualhormone". In Kimmig J (ed.). Therapie der Haut- und Geschlechtskrankheiten. Springer-Verlag. pp. 508–. ISBN 978-3-642-94850-3.
  3. ^ Vorherr H (2 December 2012). "Suppression of Action". The Breast: Morphology, Physiology, and Lactation. Elsevier Science. pp. 201–. ISBN 978-0-323-15726-1.
  4. ^ a b Defoort P, Thiery M, Baele G, Clement D, Dhont M (December 1987). "Bromocriptine in an injectable retard form for puerperal lactation suppression: comparison with Estandron prolongatum". Obstetrics and Gynecology. 70 (6): 866–869. PMID 3684122.
  5. ^ Current Medicine and Drugs. 1964. p. 32. Mixogen Injection is now available in single vials of 2 ml which replace the 1 ml ampoules hitherto supplied. It is widely used for the suppression of lactation and the single 2 ml dose pack is specially designed for obstetric indications.
  6. ^ a b Sharma CP, Chandy T (November 1989). "Influence of steroid hormones on protein-platelet interaction at the blood-polymer interface". Biomaterials. 10 (9): 609–616. doi:10.1016/0142-9612(89)90115-4. PMID 2611310. Mixogen, one 1 ml ampoule contains oestradiol benzoate I.P., 1 mg, oestradiol phenyl propionate, 4 mg, testosterone propionate I.P., 20 mg, testosterone phenyl propionate B.P., 40 mg and testosterone isocaproate B.P., 40 mg.
  7. ^ Ufer J (1 January 1978). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis [Hormone Therapy in Gynecology: Principles and Practice] (in German) (5th ed.). de Gruyter. p. 276. ISBN 978-3110066647. OCLC 924728827.
  8. ^ a b Kahr H, Müller HA (1956). "Behandlung der Menstruationsstörungen". Konservative Therapie der Frauenkrankheiten. Springer. pp. 1–85. doi:10.1007/978-3-7091-5694-0_1. ISBN 978-3-7091-5696-4.
  9. ^ "Neue Spezialitäten". Klinische Wochenschrift. 37 (13): 719–720. 1959. doi:10.1007/BF01478227. ISSN 0023-2173. S2CID 13380961.
  10. ^ Front Matter. (1953). The British Medical Journal, 2(4835). Retrieved from http://www.jstor.org/stable/20312464
  11. ^ Kaiser R (March 1984). "Duration of the climacteric syndrome in women treated by hormonal substitution and in controls". Maturitas. 5 (3): 207–213. doi:10.1016/0378-5122(84)90054-9. PMID 6727694.
  12. ^ "Estradiol". Drugs.com.
  13. ^ Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. pp. 2100, 2124–2125. ISBN 978-0-85369-840-1.
  14. ^ "IBM Watson Health Products: Please Login". www.micromedexsolutions.com.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Estradiol_benzoate/estradiol_phenylpropionate/testosterone_propionate/testosterone_phenylpropionate/testosterone_isocaproate&oldid=1189119865"